TAK-242 (Resatorvid) inhibits proinflammatory cytokine production through the inhibition of NF-κB signaling pathway in fibroblast-like synoviocytes in osteoarthritis patients

Adv Rheumatol. 2024 Jun 7;64(1):46. doi: 10.1186/s42358-024-00385-9.

Abstract

Background: Fibroblast-like synoviocytes (FLSs) are involved in osteoarthritis (OA) pathogenesis through pro-inflammatory cytokine production. TAK-242, a TLR4 blocker, has been found to have a significant impact on the gene expression profile of pro-inflammatory cytokines such as IL1-β, IL-6, TNF-α, and TLR4, as well as the phosphorylation of Ikβα, a regulator of the NF-κB signaling pathway, in OA-FLSs. This study aims to investigate this effect because TLR4 plays a crucial role in inflammatory responses.

Materials and methods: Ten OA patients' synovial tissues were acquired, and isolated FLSs were cultured in DMEM in order to assess the effectiveness of TAK-242. The treated FLSs with TAK-242 and Lipopolysaccharides (LPS) were analyzed for the mRNA expression level of IL1-β, IL-6, TNF-α, and TLR4 levels by Real-Time PCR. Besides, we used western blot to assess the protein levels of Ikβα and pIkβα.

Results: The results represented that TAK-242 effectively suppressed the gene expression of inflammatory cytokines IL1-β, IL-6, TNF-α, and TLR4 which were overexpressed upon LPS treatment. Additionally, TAK-242 inhibited the phosphorylation of Ikβα which was increased by LPS treatment.

Conclusion: According to our results, TAK-242 shows promising inhibitory effects on TLR4-mediated inflammatory responses in OA-FLSs by targeting the NF-κB pathway. TLR4 inhibitors, such as TAK-242, may be useful therapeutic agents to reduce inflammation and its associated complications in OA patients, since traditional and biological treatments may not be adequate for all of them.

Keywords: Fibroblast-like synoviocytes; IL-6; IL1-β; Osteoarthritis; TAK-242; TLR4; TNF-α.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cells, Cultured
  • Cytokines* / metabolism
  • Female
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism
  • Humans
  • Interleukin-1beta* / metabolism
  • Interleukin-6* / metabolism
  • Lipopolysaccharides* / pharmacology
  • Male
  • Middle Aged
  • NF-kappa B* / metabolism
  • Osteoarthritis / drug therapy
  • Osteoarthritis / metabolism
  • Phosphorylation
  • RNA, Messenger / metabolism
  • Signal Transduction* / drug effects
  • Sulfonamides* / pharmacology
  • Sulfonamides* / therapeutic use
  • Synoviocytes* / drug effects
  • Synoviocytes* / metabolism
  • Toll-Like Receptor 4* / metabolism
  • Tumor Necrosis Factor-alpha* / metabolism

Substances

  • ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate
  • NF-kappa B
  • Sulfonamides
  • Toll-Like Receptor 4
  • Cytokines
  • Interleukin-6
  • Interleukin-1beta
  • Tumor Necrosis Factor-alpha
  • TLR4 protein, human
  • Lipopolysaccharides
  • IL1B protein, human
  • IL6 protein, human
  • RNA, Messenger